	US 11,897,943 B2
	Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
James Mond, Silver Spring, MD (US); and Adam S. Grossman, Saddle River, NJ (US)
Assigned to ADMA BIOMANUFACTURING, LLC, Boca Raton, FL (US)
Filed by ADMA Biologics, Inc., Ramsey, NJ (US)
Filed on Aug. 9, 2021, as Appl. No. 17/397,915.
Application 17/397,915 is a continuation of application No. 16/384,334, filed on Apr. 15, 2019, granted, now 11,084,870, issued on Aug. 10, 2021.
Application 16/384,334 is a continuation of application No. 15/460,147, filed on Mar. 15, 2017, granted, now 10,259,865, issued on Apr. 16, 2019.
Prior Publication US 2022/0023339 A1, Jan. 27, 2022
Int. Cl. C07K 16/12 (2006.01); C07K 16/06 (2006.01); A61K 9/00 (2006.01); A61K 35/16 (2015.01)

CPC C07K 16/1275 (2013.01) [A61K 9/0019 (2013.01); A61K 35/16 (2013.01); C07K 16/06 (2013.01); C07K 16/065 (2013.01); C07K 2317/10 (2013.01); C07K 2317/21 (2013.01)]

15 Claims

1. A method of treating an upper respiratory tract infection, the method comprising:

administering to a subject a therapeutically effective amount of an immunotherapeutic composition comprising immune globulin prepared from pooled plasma samples from healthy adult human plasma donors vaccinated with a primary and a secondary anti-pneumococcal vaccine, wherein the pooled plasma contains opsonophagocytic antibody titers specific for at least 7 or more S. pneumonia serotypes selected from the group consisting of S. pneumonia serotypes 1, 2, 3, 4, 5, 6A, 6B, 7A, 7B, 7C, 7D, 7E, 7F, 8, 9A-9V, 12, 14, 18C, 19A-19F, 23A-23F, and 25, wherein the opsonophagocytic antibody titers specific for the 7 or more S. pneumonia serotypes are each at least 3-fold higher than the opsonophagocytic antibody titers specific for the 7 or more S. pneumonia serotypes present in a control sample, wherein the control sample is immune globulin prepared from plasma pooled from 500 or more random human plasma donors that have not been vaccinated with an anti-pneumococcal vaccine.